Literature DB >> 19918214

Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.

Mark A Travassos1, Miriam K Laufer.   

Abstract

One of the greatest obstacles to the control of malaria has been the spread of resistance to drugs used on a large scale. This review provides an update of the current understanding of the molecular basis for antimalarial drug resistance. Parasite intrinsic resistance is just one component that determines the in vivo efficacy of a drug. Human immune responses and pharmacologic properties play important roles in determining the clinical outcome of treatment. The emergence and spread of resistance also results from an interplay of these factors. Current efforts to characterize and deter resistance to new combination therapy are also discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19918214      PMCID: PMC2837525          DOI: 10.1203/PDR.0b013e3181a0977e

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  71 in total

Review 1.  A network to monitor antimalarial drug resistance: a plan for moving forward.

Authors:  Carol Hopkins Sibley; Karen I Barnes; William M Watkins; Christopher V Plowe
Journal:  Trends Parasitol       Date:  2007-11-26

2.  Evidence of artemisinin-resistant malaria in western Cambodia.

Authors:  Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda
Journal:  N Engl J Med       Date:  2008-12-08       Impact factor: 91.245

Review 3.  Erythrocyte variants and the nature of their malaria protective effect.

Authors:  Gundula Min-Oo; Philippe Gros
Journal:  Cell Microbiol       Date:  2005-06       Impact factor: 3.715

4.  Effects of alpha-thalassemia on pharmacokinetics of the antimalarial agent artesunate.

Authors:  W Ittarat; S Looareesuwan; P Pootrakul; P Sumpunsirikul; P Vattanavibool; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?

Authors:  Alexis Nzila; Edwin Ochong; Eunice Nduati; Kokwaro Gilbert; Peter Winstanley; Steve Ward; Kevin Marsh
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-05       Impact factor: 2.184

6.  Observations on monthly pyrimethamine (daraprim) prophylaxis in an East African village.

Authors:  D F CLYDE
Journal:  East Afr Med J       Date:  1954-02

7.  Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border.

Authors:  Alisa P Alker; Pharath Lim; Rithy Sem; Naman K Shah; Poravuth Yi; Denis Mey Bouth; Reiko Tsuyuoka; Jason D Maguire; Thierry Fandeur; Frederic Ariey; Chansuda Wongsrichanalai; Steven R Meshnick
Journal:  Am J Trop Med Hyg       Date:  2007-04       Impact factor: 2.345

Review 8.  Antimalarial dosing regimens and drug resistance.

Authors:  Karen I Barnes; William M Watkins; Nicholas J White
Journal:  Trends Parasitol       Date:  2008-02-11

9.  Adaptive copy number evolution in malaria parasites.

Authors:  Shalini Nair; Becky Miller; Marion Barends; Anchalee Jaidee; Jigar Patel; Mayfong Mayxay; Paul Newton; François Nosten; Michael T Ferdig; Tim J C Anderson
Journal:  PLoS Genet       Date:  2008-10-31       Impact factor: 5.917

10.  World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.

Authors:  Karen I Barnes; Niklas Lindegardh; Olumide Ogundahunsi; Piero Olliaro; Christopher V Plowe; Milijaona Randrianarivelojosia; Grace O Gbotosho; William M Watkins; Carol H Sibley; Nicholas J White
Journal:  Malar J       Date:  2007-09-06       Impact factor: 2.979

View more
  18 in total

1.  Validating a firefly luciferase-based high-throughput screening assay for antimalarial drug discovery.

Authors:  Pulin Che; Long Cui; Olaf Kutsch; Liwang Cui; Qianjun Li
Journal:  Assay Drug Dev Technol       Date:  2011-11-03       Impact factor: 1.738

2.  Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal.

Authors:  Omar Ly; Papa ElHadji Omar Gueye; Awa Bineta Deme; Therese Dieng; Aida Sadikh Badiane; Ambroise D Ahouidi; Mouhamadou Diallo; Amy K Bei; Dyann F Wirth; Souleymane Mboup; Ousmane Sarr
Journal:  Parasitol Res       Date:  2012-06-17       Impact factor: 2.289

3.  Antiplasmodial activity of extracts of Tridax procumbens and Phyllanthus amarus in in vitro Plasmodium falciparum culture systems.

Authors:  R Appiah-Opong; A K Nyarko; D Dodoo; F N Gyang; K A Koram; N K Ayisi
Journal:  Ghana Med J       Date:  2011-12

4.  Methyl-methoxylpyrrolinone and flavinium nucleus binding signatures on falcipain-2 active site.

Authors:  Olaposi I Omotuyi
Journal:  J Mol Model       Date:  2014-08-06       Impact factor: 1.810

Review 5.  Malarial hemozoin: from target to tool.

Authors:  Lorena M Coronado; Christopher T Nadovich; Carmenza Spadafora
Journal:  Biochim Biophys Acta       Date:  2014-02-17

6.  Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Harriet Mayanja-Kizza; Concepta Merry; Bob Colebunders; Jean-Pierre Van Geertruyden
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

7.  Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia.

Authors:  Teferi Eshetu; Nasir Abdo; Kunuz H Bedru; Sintayehu Fekadu; Andreas Wieser; Michael Pritsch; Thomas Löscher; Nicole Berens-Riha
Journal:  Malar J       Date:  2012-07-23       Impact factor: 2.979

8.  Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Harriet Mayanja-Kizza; Saye Khoo; Concepta Merry; Jean-Pierre Van Geertruyden
Journal:  Malar Res Treat       Date:  2011-04-06

Review 9.  Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets.

Authors:  Asrar Alam
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-03-11

10.  Use of proscribed chloroquine is associated with an increased risk of pfcrt T76 mutation in some parts of Ghana.

Authors:  Kwame K Asare; Johnson N Boampong; Richmond Afoakwah; Elvis O Ameyaw; Rakesh Sehgal; Neils B Quashie
Journal:  Malar J       Date:  2014-06-26       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.